Limits...
Clusters of multidrug-resistant Mycobacterium tuberculosis cases, Europe.

Devaux I, Kremer K, Heersma H, Van Soolingen D - Emerging Infect. Dis. (2009)

Bottom Line: Epidemiologic and molecular data were linked for 593 (39%) cases, and 672 insertion sequence 6110 DNA fingerprint patterns were reported from 19 countries.Of these patterns, 288 (43%) belonged to 18 European clusters; 7 clusters (242/288 cases, 84%) were characterized by strains of the Beijing genotype family, including the largest cluster (175/288 cases, 61%).Both clustering and the Beijing genotype were associated with strains originating in eastern European countries.

View Article: PubMed Central - PubMed

Affiliation: European Centre for Disease Prevention and Control, Stockholm, Sweden. isabelle.devaux@ecdc.europa.eu

ABSTRACT
Molecular surveillance of multidrug-resistant tuberculosis (MDR TB) was implemented in Europe as case reporting in 2005. For all new MDR TB cases detected from January 2003 through June 2007, countries reported case-based epidemiologic data and DNA fingerprint patterns of MDR TB strains when available. International clusters were detected and analyzed. From 2003 through mid-2007 in Europe, 2,494 cases of MDR TB were reported from 24 European countries. Epidemiologic and molecular data were linked for 593 (39%) cases, and 672 insertion sequence 6110 DNA fingerprint patterns were reported from 19 countries. Of these patterns, 288 (43%) belonged to 18 European clusters; 7 clusters (242/288 cases, 84%) were characterized by strains of the Beijing genotype family, including the largest cluster (175/288 cases, 61%). Both clustering and the Beijing genotype were associated with strains originating in eastern European countries. Molecular cluster detection contributes to identification of transmission profile, risk factors, and control measures.

Show MeSH

Related in: MedlinePlus

Description of MDR TB cases in Europe selected for data analysis, January 2003–July 2007. RFA does not include data from Germany and Lithuania. MDR TB, multidrug-resistant tuberculosis; SLD, second-line drug; DST, drug-susceptibility test; RFA, risk factor analysis. *Countries: Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Ireland, Israel, Lithuania, the Netherlands, Norway, Spain, Sweden, Switzerland, and the United Kingdom.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2744220&req=5

Figure 1: Description of MDR TB cases in Europe selected for data analysis, January 2003–July 2007. RFA does not include data from Germany and Lithuania. MDR TB, multidrug-resistant tuberculosis; SLD, second-line drug; DST, drug-susceptibility test; RFA, risk factor analysis. *Countries: Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Ireland, Israel, Lithuania, the Netherlands, Norway, Spain, Sweden, Switzerland, and the United Kingdom.

Mentions: Laboratories from 19 countries sent 672 IS6110 RFLP patterns to the RIVM, 593 of which also had epidemiologic information and were linked to the epidemiologic database maintained by EuroTB (Table 1; Figure 1). Linkage of molecular and epidemiologic data was not possible for data from the United Kingdom and for data on a few cases from 6 other countries. The average proportion of MDR TB cases documented with both epidemiologic and genotyping data in 18 countries was 593/1,523 (39%), varying from 9% to 100%. After we removed data from 2 countries with low data completeness for genotypes (Germany and Lithuania), we found that the average proportion of MDR TB cases with both epidemiologic and genotyping data was 68%. Individual data on second-line drug tests for 2 to 5 second-line drugs included in the XDR TB definition (22) were reported for 1,302 cases by 16 countries from January 2003 through July 2007 (Figure 1).


Clusters of multidrug-resistant Mycobacterium tuberculosis cases, Europe.

Devaux I, Kremer K, Heersma H, Van Soolingen D - Emerging Infect. Dis. (2009)

Description of MDR TB cases in Europe selected for data analysis, January 2003–July 2007. RFA does not include data from Germany and Lithuania. MDR TB, multidrug-resistant tuberculosis; SLD, second-line drug; DST, drug-susceptibility test; RFA, risk factor analysis. *Countries: Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Ireland, Israel, Lithuania, the Netherlands, Norway, Spain, Sweden, Switzerland, and the United Kingdom.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2744220&req=5

Figure 1: Description of MDR TB cases in Europe selected for data analysis, January 2003–July 2007. RFA does not include data from Germany and Lithuania. MDR TB, multidrug-resistant tuberculosis; SLD, second-line drug; DST, drug-susceptibility test; RFA, risk factor analysis. *Countries: Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Ireland, Israel, Lithuania, the Netherlands, Norway, Spain, Sweden, Switzerland, and the United Kingdom.
Mentions: Laboratories from 19 countries sent 672 IS6110 RFLP patterns to the RIVM, 593 of which also had epidemiologic information and were linked to the epidemiologic database maintained by EuroTB (Table 1; Figure 1). Linkage of molecular and epidemiologic data was not possible for data from the United Kingdom and for data on a few cases from 6 other countries. The average proportion of MDR TB cases documented with both epidemiologic and genotyping data in 18 countries was 593/1,523 (39%), varying from 9% to 100%. After we removed data from 2 countries with low data completeness for genotypes (Germany and Lithuania), we found that the average proportion of MDR TB cases with both epidemiologic and genotyping data was 68%. Individual data on second-line drug tests for 2 to 5 second-line drugs included in the XDR TB definition (22) were reported for 1,302 cases by 16 countries from January 2003 through July 2007 (Figure 1).

Bottom Line: Epidemiologic and molecular data were linked for 593 (39%) cases, and 672 insertion sequence 6110 DNA fingerprint patterns were reported from 19 countries.Of these patterns, 288 (43%) belonged to 18 European clusters; 7 clusters (242/288 cases, 84%) were characterized by strains of the Beijing genotype family, including the largest cluster (175/288 cases, 61%).Both clustering and the Beijing genotype were associated with strains originating in eastern European countries.

View Article: PubMed Central - PubMed

Affiliation: European Centre for Disease Prevention and Control, Stockholm, Sweden. isabelle.devaux@ecdc.europa.eu

ABSTRACT
Molecular surveillance of multidrug-resistant tuberculosis (MDR TB) was implemented in Europe as case reporting in 2005. For all new MDR TB cases detected from January 2003 through June 2007, countries reported case-based epidemiologic data and DNA fingerprint patterns of MDR TB strains when available. International clusters were detected and analyzed. From 2003 through mid-2007 in Europe, 2,494 cases of MDR TB were reported from 24 European countries. Epidemiologic and molecular data were linked for 593 (39%) cases, and 672 insertion sequence 6110 DNA fingerprint patterns were reported from 19 countries. Of these patterns, 288 (43%) belonged to 18 European clusters; 7 clusters (242/288 cases, 84%) were characterized by strains of the Beijing genotype family, including the largest cluster (175/288 cases, 61%). Both clustering and the Beijing genotype were associated with strains originating in eastern European countries. Molecular cluster detection contributes to identification of transmission profile, risk factors, and control measures.

Show MeSH
Related in: MedlinePlus